Sol-Gel Technologies Ltd. (SLGL)
Summary
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of $0.39.
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
Sol-Gel Technologies Ltd. (SLGL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sol-Gel Technologies Ltd. ever had a stock split?
Sol-Gel Technologies Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Moshe Arkin CEO | NASDAQ (CM) Exchange | M8694L137 CUSIP |
| IL Country | 34 Employees | - Last Dividend | 5 May 2025 Last Split | 23 Jan 2018 IPO Date |
Overview
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company in the clinical stage, based in Israel, that specializes in the development and commercialization of innovative topical dermatological drugs. Leveraging its proprietary microencapsulation delivery system, the company is devoted to addressing unmet medical needs by creating new therapies with potential benefits over existing treatments. Formed in 1997, Sol-Gel has established a significant footprint in dermatology, driven by its robust pipeline of product candidates and a strategic collaboration with Perrigo. The company's primary focus is on diseases such as acne vulgaris, papulopustular rosacea, palmoplantar keratoderma, and rare skin conditions including Gorlin Syndrome.
Products and Services
- Twyneo
- Epsolay
- SGT-210
- SGT-610
- Erlotinib and Tapinarof
- Generic Topical Dermatological Drug Products
A groundbreaking, once-daily, non-antibiotic topical cream designed for the effective treatment of acne vulgaris. Twyneo has successfully completed Phase III clinical trials, demonstrating its potential as a leading acne treatment.
A novel, once-daily topical cream developed for treating papulopustular rosacea, Epsolay has completed Phase III clinical trials. Its microencapsulation delivery system uniquely positions it as a potentially transformative therapeutic option.
Currently in Phase I clinical trials, SGT-210 represents Sol-Gel's efforts to treat palmoplantar keratoderma, emphasizing the company's dedication to addressing rare and challenging dermatological conditions.
Targeting the rare disease Gorlin Syndrome, SGT-610 has completed Phase II clinical trials. This highlights Sol-Gel’s commitment to developing solutions for lesser-known, yet impactful, skin diseases.
These promising compounds are in development to treat other rare skin indications, showcasing Sol-Gel's broad approach to leveraging its microencapsulation technology for various therapeutic applications.
Alongside its innovative product pipeline, Sol-Gel is also involved in the development of generic topical dermatological drugs, aiming to offer effective and accessible treatment options within the broader market.
